Results 211 to 220 of about 75,203 (286)

Bacillus cereus Sepsis in a Patient with Severe Alcoholic Hepatitis. [PDF]

open access: yesIntern Med
Suto K   +5 more
europepmc   +1 more source

S3 guideline diagnostics and therapy in alopecia areata – Part 2: Therapy, psychosocial and cosmetic support

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary This second part of the S3 guideline on the diagnosis and treatment of alopecia areata (AA), presents key recommendations on topical and systemic therapy, quality of life and support services. The first part of the guideline, published separately, covers the definition and content of epidemiology and diagnosis as well as comorbidities, risk and
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote   +10 more
wiley   +1 more source

Glucagon‐Like Peptide‐1 Receptor Agonists and Incident Major Adverse Liver Outcomes in People With Type 2 Diabetes and Metabolic Dysfunction‐Associated Steatotic Liver Disease

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Treatment options for metabolic dysfunction‐associated steatotic liver disease (MASLD) are limited. While glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) and sodium‐glucose cotransporter‐2 (SGLT‐2) inhibitors improve cardiovascular outcomes, comparative effectiveness on liver‐related outcomes remains unclear.
Gregor A. Maier   +4 more
wiley   +1 more source

Hepatic Safety of Orforglipron in Adults With Obesity or Overweight and/or Type 2 Diabetes: A Pooled Analysis of the Orforglipron Phase 3 Clinical Trials

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Orforglipron is a novel small‐molecule, once daily oral non‐peptide GLP‐1 receptor agonist. The hepatic safety profile in adults with obesity or overweight and/or type 2 diabetes (T2D) across seven orforglipron Phase 3 clinical trials was assessed.
Sean Wharton   +5 more
wiley   +1 more source

Hand Hygiene Accuracy of Students and Staff at a Dutch Dental School

open access: yesEuropean Journal of Dental Education, EarlyView.
ABSTRACT Introduction Oral health care professionals continuously come into contact with bodily fluids containing many pathogens. Hand hygiene should be used to prevent cross transmission. We aimed to examine the accuracy of application of alcohol‐based hand rub (ABHR) according to the WHO hand hygiene steps at a dental school.
Ilona Francisca Persoon   +1 more
wiley   +1 more source

Proteolytic remodelling of the extracellular matrix by pericytes

open access: yesThe FEBS Journal, EarlyView.
Pericytes are specialised perivascular cells intimately connected with endothelial cells and essential for the maintenance of vascular beds. They contribute to the formation and remodelling of the extracellular matrix by actively secreting proteases and protease inhibitors.
Tina Burkhard   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy